Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Notal Vision to Present on Home-based Optical Coherence Tomography at the Upcoming Ophthalmology Innovation Summit in New Orleans

Notal Vision
Posted on: 08 Nov 17
Notal Vision to Present on Home-based Optical Coherence Tomography at the Upcoming Ophthalmology Innovation Summit in New Orleans Chief Medical Officer to introduce novel solution for home disease detection with diagnostic testing

PR Newswire

MANASSAS, Va., Nov. 8, 2017

MANASSAS, Va., Nov. 8, 2017 /PRNewswire/ -- Notal Vision®, Ltd., a privately-held ophthalmic company focused on an innovative, cloud-based platform for remote diagnostic testing, has announced that Susan Orr, Chief Medical Officer and Vice President of Medical Affairs, will be presenting at the upcoming Ophthalmology Innovation Summit (OIS) in New Orleans, LA, on November 9th, 2017.

"Notal is proud to have been selected to present at this competitive and highly anticipated event. The OIS provides a remarkable forum for addressing key issues within the ophthalmic field and showcasing promising innovation. We are thrilled and honored to be recognized as one of the most innovative companies in eye care today. I look forward to sharing the exciting details about our Home OCT device in development," said Susan Orr.

Notal Vision is committed to establishing a new paradigm for detecting ophthalmic disease and optimizing visual outcomes. Home-based OCT leverages the validated, patient-activated platform first employed by the ForeseeHome® application for patients at risk of vision loss from wet age-related macular degeneration (AMD), and expands the product portfolio to create a complete, personalized diagnostic testing system for retinal diseases. The technology is complementary to in-office OCT, and uses spectral domain (SD) technology along with a proprietary algorithm, the Notal OCT Analyzer (NOA). A study published by Chakravarthy, et al. demonstrated that fluid identification using NOA was comparable to that of individual retina specialists when each was compared to a Reading Center with 3 retinal specialists.

"There are highly effective treatment options for wet AMD, with a number of emerging therapies on the horizon. However, real-world outcomes have not replicated the efficacy observed in clinical trials and this can be attributed, in part, to under-treatment of disease," stated Susan Orr. "Home OCT diagnostic testing addresses under-treatment by personalizing wet AMD management. Detecting lesion activity as soon as it occurs will facilitate timely treatment, improving long-term visual acuity maintenance. Home OCT will offer physicians unique and actionable inter-visit disease knowledge to customize office appointments that meet individual patient needs."

About Notal Vision's Cloud-Based Platform

Notal Vision has established a seamless, cloud-based platform that connects healthcare providers and their patients through personalized, remote detection of ocular diseases. ForeseeHome®, the first application of Notal Vision's cloud-based platform, is an FDA-cleared diagnostic testing device which uses this platform to monitor visual changes in patients at risk of vision loss from wet AMD. ForeseeHome is covered by Medicare and most private insurances. To learn more, visit

The Notal Home OCT, the next application of Notal's cloud-based platform, will enable patients to perform technician-free OCT at home with self-guided fixation – critical components, especially for elderly patients. The Notal OCT Analyzer (NOA), a proprietary machine-learning algorithm developed in-house, performs automated analysis of the Notal Home OCT scans and generates an alert report to the physician when fluid is present in the retina. The NOA sends reports to physicians for review that ranks OCT cross sections from most to least fluid with associated images, at which point the patient may be brought to the office for evaluation and treatment. NOA can also analyze the output of other commercial OCT devices, and published study data indicate that the performance of NOA was similar to that of retina physicians when each was compared to a panel of experts. The Notal Home OCT has the potential to truly individualize retinal disease management.

About Notal Vision, Ltd.

Notal Vision was founded by two ophthalmologists and is committed to providing the eyecare community with innovative, home-based, diagnostic technologies that support visual health in patients with retinal diseases. ForeseeHome is the first FDA-cleared remote diagnostic testing device that detects and characterizes visual distortion in AMD patients as an aid to monitoring choroidal neovascularization progression. To learn more, visit

View original content:

SOURCE Notal Vision

PR Newswire

Last updated on: 08/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.